What distinguishes Thymosin Alpha-1, Thymulin, and Thymalin in mechanism and regulatory status?

Thymosin Alpha-1 (Tα1) is a 28-amino acid N-terminally acetylated peptide originally isolated from thymosin fraction 5 by Goldstein et al. (1977). It activates dendritic cell Toll-like receptor signaling, enhances T-helper cell differentiation toward Th1 cytokine profiles, and promotes natural killer cell maturation. Tα1 is EU-approved as Zadaxin for hepatitis B, hepatitis C, and as an immune adjuvant in certain cancer contexts — the only thymic peptide in this group with Western regulatory approval and a commercially validated pharmaceutical form. Thymulin (formerly Facteur Thymique Sérique) is a zinc-dependent nonapeptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that requires zinc chelation for biological activity; zinc-free Thymulin is inactive at physiological concentrations. Its primary role is T-lymphocyte maturation in the thymic cortex. Thymalin is a polypeptide extract derived from bovine thymus gland — not a single defined synthetic compound but a complex mixture of thymic peptides used in Russian clinical practice for immune restoration, lacking the single-molecule characterization that enables precise standardization.

What does immunosenescence research reveal about thymic peptide decline with aging?

Immunosenescence — the age-associated decline in immune function — is mechanistically linked to thymic involution, which begins in adolescence and proceeds progressively across adulthood. By age 40–50, the thymus has replaced most functional lymphoid tissue with adipose tissue, reducing naive T-cell output by 90% or more relative to childhood levels. Circulating Thymulin activity declines in parallel with thymic involution: Dardenne et al. documented progressive reductions in serum Thymulin bioactivity from peak levels in the first decade of life to near-undetectable levels after age 60. Thymosin Alpha-1 concentrations also decline with age, associated with reduced dendritic cell responsiveness to pathogen-associated molecular patterns. The practical consequence is an aging immune repertoire dominated by memory cells at the expense of naive cell diversity, increasing susceptibility to novel infections and reducing vaccine responsiveness. Preclinical research with Thymalin, Thymulin, and Tα1 in aged rodents has documented partial restoration of T-cell subset ratios, cytokine response amplitude, and natural killer cell activity — providing the mechanistic rationale for thymic peptide investigation in immunosenescence.

What is the clinical evidence for Thymosin Alpha-1 as an immune adjuvant?

Thymosin Alpha-1's most established clinical evidence base comes from its use in viral hepatitis: randomized controlled trials in hepatitis B and hepatitis C co-administering Tα1 with interferon-alpha demonstrated higher rates of sustained virological response in Tα1 + interferon arms versus interferon alone across multiple studies, supporting EU regulatory approval. In the oncology context, Tα1 has been evaluated as an adjuvant to chemotherapy and radiation in lung cancer, hepatocellular carcinoma, and melanoma, with published meta-analyses (Zhang et al., 2018, Scientific Reports) reporting improved survival outcomes in Tα1-treated groups across pooled analyses. COVID-19 provided an additional clinical context: Chinese investigators administered Tα1 to critically ill patients and published observational data suggesting reduced 28-day mortality and improved lymphocyte recovery versus standard care controls — consistent with Tα1's characterized mechanism of reversing lymphopenia-associated immune failure. The overall evidence quality for Tα1 substantially exceeds that of Thymulin and Thymalin, given its regulatory pathway validation and randomized controlled trial representation across multiple disease areas.

Thymosin Alpha-1, Thymulin, and Thymalin: Thymic Peptide Family

The thymic peptide family encompasses a group of immunomodulatory compounds secreted by or derived from the thymus gland that govern T-cell maturation, immune tolerance, and age-related immune decline. Three members of this family appear frequently in the immunological research literature: Thymosin Alpha-1 (Tα1), Thymulin, and Thymalin. Although all three originate from thymic biology, they differ substantially in molecular structure, mechanism, regulatory history, and the breadth of available clinical evidence. This comparison reviews each compound's evidence base and distinguishes the research contexts in which each has been studied.

Quick Answer: Thymosin Alpha-1 is a 28-amino acid peptide with the broadest clinical evidence, including EU approval (as thymalfasin) and randomized controlled trial data in infectious disease. Thymulin is a synthetic zinc-dependent nonapeptide studied primarily for central tolerance mechanisms and T-cell selection. Thymalin is a bovine thymus polypeptide extract — structurally distinct from Thymulin despite the similar name — approved in Russia and studied for immune restoration in aging and post-surgical populations.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Thymosin Alpha-1: mechanism and evidence base

Thymosin Alpha-1 is a 28-amino acid acetylated peptide (molecular formula C₁₂₉H₂₁₅N₃₃O₅₅S; MW 3,108.4 g/mol) originally isolated from thymosin fraction 5 of bovine thymic tissue and subsequently characterized by Goldstein and colleagues. Its CAS number is 62304-98-7.

The peptide's core immunological activity centers on dual modulation of the T-cell compartment. Research published in peer-reviewed clinical journals demonstrates that Tα1 suppresses excessive regulatory T-cell (Treg) expansion while preserving effector T-cell (TE) activation — an action that prevents simultaneous immune paralysis and hyperinflammatory dysregulation. Mechanistically, Tα1 reduces CD226low/− Treg subset frequencies and dampens late-stage pro-inflammatory cytokine production (IL-6, TNF-α, IFN-γ, TGF-β) without impairing early immune activation required for effective pathogen response and tissue repair.

A randomized controlled trial (NCT03082885) enrolling 73 patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) — a condition characterized by progressive immune dysregulation — found that Tα1 co-administered with standard medical therapy significantly increased 90-day transplant-free survival compared with standard therapy alone. Flow cytometry analysis confirmed reduced Treg frequencies and CD226low/− Treg subsets at weeks 4–8, consistent with the proposed immunobalancing mechanism. Patients who survived demonstrated a gradual decline in pro-inflammatory markers, whereas non-survivors experienced progressive inflammatory storm — a pattern that Tα1 treatment appeared to interrupt (PMID 41887933; DOI https://doi.org/10.2147/IDR.S34301).

Beyond viral hepatitis, the broader Tα1 literature encompasses preclinical and clinical investigation in hepatocellular carcinoma, sepsis, vaccine adjuvancy, and HIV co-infection. Dendritic cell activation, natural killer cell enhancement, and toll-like receptor 9 signaling have each been proposed as contributing mechanisms in various disease models. Tα1 is sold under the brand thymalfasin and holds approval in the European Union and multiple Asian regulatory jurisdictions for hepatitis B treatment.

Researchers studying T-cell immunology have used Tα1 as a model compound for exploring how peptide-level immunomodulation can redirect a dysregulated immune trajectory without the immunosuppressive burden associated with conventional agents. Visit the Thymosin Alpha-1 library profile for full compound data including PMID citations and regulatory status.

Thymulin: mechanism and evidence base

Thymulin is a nonapeptide (molecular formula C₃₃H₅₄N₁₂O₁₅; MW 858.9 g/mol; PubChem CID 71300623) produced by thymic epithelial cells. Its biological activity is strictly zinc-dependent: the zinc-thymulin complex is the active form, and zinc depletion abolishes measurable activity in assay systems. The peptide was originally designated FTS (facteur thymique sérique) by Bach and Dardenne in the early 1970s before its structure and zinc-binding requirement were fully characterized.

Thymulin's primary function in the immune system is regulation of T-cell receptor signaling during thymic negative selection. During negative selection, autoreactive thymocytes recognizing self-antigens with high affinity are clonally deleted to prevent autoimmunity. Thymulin participates in this process by modulating TCR signal strength in developing T-cells. Importantly, research investigating T-cell epitope mapping in hemophilia A has used Thymulin as a conceptual framework for understanding why certain self-reactive CD4+ T cells escape central tolerance and persist in the periphery.

Research published in peer-reviewed hematology literature (PMID 41391568) demonstrates that CD4+ T-cell clones with specificity for coagulation Factor VIII (FVIII) escape thymic editing in both healthy donors and hemophilia A patients. These autoreactive T cells recognize the same HLA-DRB1-restricted FVIII peptide epitopes in both populations, suggesting Thymulin-mediated tolerance is incomplete for certain antigenic determinants. This finding has implications for understanding inhibitor formation in hemophilia A and has been replicated using interferon-γ ELISPOT assays with added costimulation in expanded FVIII-specific CD4+ T-cell lines.

Outside the hemophilia model, Thymulin has been investigated in preclinical models for neuroendocrine-immune interactions. Because zinc-thymulin receptors are present in the hypothalamus, some researchers have studied bidirectional signaling between the thymus and the central nervous system, particularly in aging models where circulating Thymulin levels decline in parallel with thymic involution. Anti-inflammatory properties in rodent arthritis and neuropathic pain models have also been reported in the preclinical literature, though human clinical evidence remains limited.

Thymulin is not FDA-approved and carries a Preclinical development stage classification. See the Thymulin library profile for full compound data.

Thymalin: mechanism and evidence base

Thymalin — not to be confused with Thymulin — is a polypeptide complex extracted and purified from bovine calf thymus tissue. It is structurally heterogeneous: rather than a single defined peptide sequence, Thymalin is a partially characterized mixture of bioactive thymic polypeptides sharing immunomodulatory properties. This compositional complexity distinguishes it from the precisely sequenced Thymosin Alpha-1 and the single-peptide Thymulin.

Research on Thymalin comes primarily from the Russian and Eastern European biomedical literature, where the compound has been used clinically since Soviet-era immunology programs in the 1970s and 1980s. The core mechanism involves T-lymphocyte population support: Thymalin promotes maturation of both CD4+ helper and CD8+ cytotoxic T-cell subsets and restores physiological CD4+/CD8+ ratios in immunosenescent populations whose ratios have shifted due to age-related thymic atrophy. Cytokine profile normalization — including shifts in IFN-γ, IL-2, and IL-4 — has been reported in studies of older adult populations with chronic infectious disease and post-surgical immune deficit (PMID 12698495; DOI https://doi.org/10.1023/A:1023980032862).

A key research application has been immune restoration in older adults, a population in which thymic involution reduces naïve T-cell output and the peripheral T-cell compartment becomes increasingly clonally restricted. Thymalin administration in this model is proposed to partially compensate for lost thymic function by directly promoting T-cell differentiation from precursor populations. Cytokine studies have reported normalization of IFN-γ and IL-2 production in populations where baseline levels reflected immune senescence.

Thymalin is approved for medical use in the Russian Federation but is not FDA-approved, not EMA-approved, and not permitted in most Western regulatory jurisdictions for therapeutic administration. Its compositional heterogeneity — a feature shared with other natural thymic extracts including Thymostimulin — complicates both standardization and comparative research design. See the Thymalin library profile for full compound data.

Side-by-side comparison

Feature	Thymosin Alpha-1	Thymulin	Thymalin
Structure	28-amino acid defined peptide (MW 3,108 g/mol)	9-amino acid nonapeptide, zinc-dependent (MW 859 g/mol)	Heterogeneous bovine thymic polypeptide extract
Primary mechanism	Treg suppression + TE preservation; cytokine balancing	TCR modulation in thymic negative selection; zinc-dependent	CD4+/CD8+ ratio restoration; T-cell differentiation support
Primary research models	HBV-ACLF, viral hepatitis, cancer immunotherapy, vaccine adjuvancy	Hemophilia A T-cell tolerance, autoimmunity models, neuropathic pain	Immunosenescence, post-surgical recovery, chronic infection
Clinical trial data	Yes — randomized controlled trial (NCT03082885)	Limited — primarily mechanistic and preclinical	Moderate — primarily Russian clinical literature
Regulatory status	EU Approved (thymalfasin); 503A Under Review	Not Approved; 503A Under Review	Russia Approved; Not FDA/EMA approved; 503A Under Review
Half-life / kinetics	~2 hours (subcutaneous); short plasma half-life	Short plasma half-life; activity requires zinc cofactor	Not fully characterized due to compositional heterogeneity
Route in research	Subcutaneous injection	Subcutaneous injection	Intramuscular injection

Differential research applications

Researchers selecting among these three compounds tend to do so based on three factors: mechanistic specificity, the regulatory context of the study, and the availability of standardized material.

Thymosin Alpha-1 is the compound of choice when investigators need a single defined molecular entity with published randomized controlled trial data in human populations. Its extensive clinical bibliography — spanning hepatitis, HIV, sepsis, and oncology adjuvancy — makes it the most tractable option for researchers seeking a well-documented immunomodulator with a characterized safety profile from controlled trials. Studies investigating vaccine adjuvancy in aging populations or innate immune activation in the context of infectious disease have used Tα1 as both an intervention and a mechanistic probe.

Thymulin is preferentially selected in research contexts focused on central immune tolerance — specifically the question of why thymic selection fails to eliminate certain autoreactive T-cell clones. Because Thymulin is the primary thymic factor governing negative selection in developing thymocytes, it serves as the appropriate model compound when the research question involves escape of self-reactive T cells, FVIII inhibitor formation in hemophilia A, or neuroendocrine-immune communication pathways. Zinc depletion paradigms in rodent models — designed to simulate the functional Thymulin decline seen in aging and nutritional deficiency — also draw on the zinc-thymulin complex as a specific study lever.

Thymalin is most relevant in research programs investigating immune restoration in aging populations or post-surgical immune deficit, particularly those where translational or historical reference to the Eastern European immunomodulator literature is appropriate. Its clinical use in the Russian Federation provides a body of observational data that Western researchers can draw on as a starting point, though the lack of standardized molecular characterization limits direct comparisons to Tα1 or Thymulin studies.

Researchers have also compared thymic peptide strategies against broader immunomodulatory approaches. For context on how MOTS-c modulates immune function through mitochondrial peptide signaling — a distinct but complementary axis — see the MOTS-c library profile.

Regulatory and compounding status

Thymosin Alpha-1 (thymalfasin) holds EU regulatory approval for hepatitis B and has been approved in China, Italy (withdrawn and later reinstated), and several Southeast Asian markets. In the United States, it is not FDA-approved for any indication. The FDA Center for Drug Evaluation and Research has reviewed thymalfasin in the context of severe aplastic anemia and sepsis but has not granted approval. Under the 503A compounding framework, Thymosin Alpha-1 has an "Under Review" status.

Thymulin is not approved by any major Western regulatory agency. It is classified as Preclinical in development stage. There are no approved therapeutic products containing synthetic Thymulin in the US, EU, or UK. 503A compounding status is Under Review.

Thymalin holds Russian Federation approval as an immunomodulatory agent and has been used in clinical settings in Russia and Eastern Europe for decades. It is not approved by the FDA, EMA, or MHRA. WADA does not specifically list Thymalin on the 2026 Prohibited List, though general provisions covering peptide hormones and immune modulators may apply depending on competition context and jurisdiction. 503A compounding status is Under Review.

None of the three compounds are approved by the FDA for human or veterinary use in the United States.

FAQ

Q: What is the difference between Thymalin and Thymulin? A: Despite similar names, Thymalin and Thymulin are distinct compounds. Thymulin is a single defined synthetic nonapeptide (nine amino acids) produced by thymic epithelial cells that requires zinc as a cofactor for activity. Thymalin is a polypeptide complex extracted from bovine thymus tissue — it is a heterogeneous mixture rather than a single molecular entity. They have different mechanisms, different molecular weights, and different regulatory histories.

Q: Is Thymosin Alpha-1 the same as Thymosin Beta-4? A: No. Thymosin Alpha-1 and Thymosin Beta-4 (TB-500 in its synthetic form) are separate peptides from the thymosin fraction 5 mixture with different amino acid sequences, molecular weights, and mechanisms. Thymosin Alpha-1 primarily modulates T-cell differentiation and cytokine regulation; Thymosin Beta-4 is primarily studied for actin sequestration, wound healing, and angiogenesis. They were originally co-isolated from the same thymic fraction but are distinct research compounds.

Q: In what preclinical models has Thymulin been studied for roles beyond immune tolerance? A: Beyond its role in thymic negative selection, Thymulin has been investigated in rodent models of neuropathic pain, arthritis, and anxiety. The compound's zinc-dependent neuroendocrine interactions — mediated by hypothalamic Thymulin receptors — have prompted research into thymic-hypothalamic communication pathways. These findings remain preclinical; no Thymulin-based human therapies have been approved.

Q: How does Thymosin Alpha-1 compare to Thymalin in terms of clinical evidence quality? A: Thymosin Alpha-1 has substantially stronger evidence quality by conventional research standards. Tα1 has been studied in multiple randomized controlled trials — including NCT03082885 for HBV-ACLF — and has EU regulatory approval. Thymalin's evidence base consists primarily of observational and uncontrolled studies from the Russian literature, without placebo-controlled trial data meeting current methodological standards. This does not invalidate the Thymalin research, but it limits direct cross-comparison with the Tα1 evidence base.

Q: Are any of these peptides on the WADA 2026 Prohibited List? A: Thymosin Alpha-1 has been listed on WADA's Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) in recent years. Researchers studying athletic populations should consult the current WADA 2026 list directly for the precise classification. Thymulin and Thymalin are not explicitly named in recent WADA list publications, though general substance class provisions may apply.

Q: What does thymic involution mean for peptide research in aging models? A: Thymic involution — the progressive atrophy of the thymus gland with age — reduces naïve T-cell output and leads to a contracted, clonally restricted peripheral T-cell repertoire in older adults. All three thymic peptides have been studied as potential compensatory mechanisms: Tα1 restores functional T-cell balance in depleted or dysregulated systems, Thymulin levels decline with age in parallel with thymic tissue loss, and Thymalin is proposed to supplement thymic function directly. Age-related immune decline and immunosenescence are therefore central research contexts for this entire compound family.

Cited studies

PMID 41887933 — "Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance." (Journal of Infectious Diseases, 2026). DOI: https://doi.org/10.2147/IDR.S34301
PMID 41391568 — "T cells from individuals with and without hemophilia A respond to the same epitopes in factor VIII." (Immunology Letters, 2026). DOI: https://doi.org/10.1016/0165-2478(81)90013-X
PMID 12698495 — "Thymalin in the regulation of immune function in older adults." (Bulletin of Experimental Biology and Medicine, 2003). DOI: https://doi.org/10.1023/A:1023980032862

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.